- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Pharmacovigilance outsourcing: Ensuring a positive experience
Karen Johnstone and Sabine Richter discuss current outsourcing practices and tips for selecting a service provider to ensure a successful relationship.
-
Longitudinal qualitative research - Capturing the patient voice; enhancing patient centricity
Outcomes researchers Alexia Marrel and Sally Lanar share insights on longitudinal qualitative research - what it is, when and how it can be used and the key factors for success when using this type of research.
-
Nominations now open for ‘Company of the Year’ Award 2022
This article features commentary from CEO Steve Cutler about ICON being awarded 2021 Company of the Year.
-
-
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
-
The cross-over of statistical thinking and practices: A pandemic catalyst
This article focuses on what others could learn from good statistical practices in drug development and considers areas where drug development could benefit from some fresh thinking
-
Improving early phase oncology clinical trial design: A case study
Tim Clark, VP Drug Development Solutions and Alan Phillips, Sr. Director Biostatistics present a case study on the first in human Bayesian Optimal Interval design.
-
ICON wins ‘Company of the Year’ at the Business & Finance Awards 2022
Steve Culter gives insight into ICON as a company along with his thoughts on winning this award.
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
The surge of digital health technologies modernising clinical research
Dr. Isaac R. Rodriguez-Chavez outlines the key considerations when developing digital health technologies.